Additionally, as CRIP1 and LSP1 are expressed on leukemia and cytotoxic immune cells, functional investigation of CRIP1 and LSP1 by AML cells or immune cells from TIME in vitro and in vivo assays will consolidate the dual-targeting treatment strategy for AML. The gene discussed is CRIP1; the disease is acute myeloid leukemia.